scholarly journals Dipeptidyl peptidase-4 inhibitors as preferable oral hypoglycemic agents in terms of treatment satisfaction: Results from a multicenter, 12-week, open label, randomized controlled study in Japan (PREFERENCE 4 study)

2017 ◽  
Vol 9 (1) ◽  
pp. 137-145 ◽  
Author(s):  
Hitoshi Ishii ◽  
Yasuaki Hayashino ◽  
Yasuhiro Akai ◽  
Matahiro Yabuta ◽  
Satoru Tsujii
Keyword(s):  
Treatment Satisfaction ◽  
Dipeptidyl Peptidase ◽  
Randomized Controlled Study ◽  
Hypoglycemic Agents ◽  
Controlled Study ◽  
Oral Hypoglycemic Agents ◽  
Open Label ◽  
Dipeptidyl Peptidase 4 ◽  
Randomized Controlled ◽  
Dipeptidyl Peptidase 4 Inhibitors

scholarly journals Hypoglycemic Coma in a Hemodialysis Patient Receiving Blood Glucose-Lowering Therapy With the Single Agent Teneligliptin

2018 ◽  
Vol 11 ◽  
pp. 117954761876335 ◽  
Author(s):  
Takumi Minezumi ◽  
Shin-ichi Takeda ◽  
Yusuke Igarashi ◽  
Kentaro Sato ◽  
Yoshiaki Murakami ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Single Agent ◽  
Severe Hypoglycemia ◽  
Dipeptidyl Peptidase ◽  
Hypoglycemic Agents ◽  
Tolerability Profile ◽  
Oral Hypoglycemic Agents ◽  
Dipeptidyl Peptidase 4 ◽  
Hypoglycemic Coma ◽  
Dipeptidyl Peptidase 4 Inhibitors

Blood glucose management in patients undergoing dialysis is clinically challenging. In this population, most conventional oral hypoglycemic agents are contraindicated, especially from the perspective of pharmacokinetics. Dipeptidyl peptidase-4 inhibitors exert unique pharmacologic actions via glucose-dependent mechanism and have an excellent tolerability profile with a very low risk of hypoglycemia. Furthermore, the literature reports that some dipeptidyl peptidase-4 inhibitors such as teneligliptin can be administered at the usual dose, regardless of a patient’s level of renal impairment. In this article, we report a case of hypoglycemic coma with a blood glucose level of 23 mg/dL. The patient became fully conscious shortly after receiving a glucose injection; however, severe hypoglycemia recurred for approximately 1.5 days. It eventually disappeared on the discontinuation of teneligliptin, which was the only antidiabetic agent that he had received. The present case may provide deep insights into promoting the safe use of hypoglycemic agents in patients undergoing dialysis.

Clinical efficacy of a herbo-mineral Unani formulation in scabies: an open-label randomized controlled study

2015 ◽  
Vol 15 (3) ◽  
pp. 173-181 ◽  
Author(s):  
Jameelur Rahman ◽  
Akhtar H. Farooqi ◽  
Arshiya Sultana ◽  
Khaleequr Rahman ◽  
Ateequr Rahman
Keyword(s):  
Clinical Efficacy ◽  
Randomized Controlled Study ◽  
Controlled Study ◽  
Open Label ◽  
Randomized Controlled
Sign in / Sign up

Export Citation Format

Share Document